業績

  • 2013年

    1. Bian Z, Furuya N, Zheng D-M, Oliva Trejo JA, Tada N, Ezaki J, Ueno T. Ferulic acid induces mTor inactivation in cultured mammalian cells. Biol Pharm Bull. 2013; 36(1): 120-124.

    2. Kawano S, Lin Q, Amano H, Kaneko T, Nishikawa K, Tsurui H, Tada N, Nishimura H, Takai T, Shirai T, Takasaki Y, Hirose S. Phenotype conversion from rheumatoid arthritis to systemic lupus erythematosus by introduction of Yaa mutation into FcgRIIB-deficient C57BL/6 mice. Eur J Immunol. 2013 Mar; 43(3): 770-778.

    3. Koike M, Tanida I, Nanao T, Tada N, Iwata J-I, Ueno T, Kominami E and Uchiyama Y. Enrichment of GABARAP relative to LC3 in the axonal initial segments of neurons. PLOS ONE. 2013 May; 8(5): e63568.

    4. Miyajima M, Nakajima M, Motoi Y, Moriya M, Sugano H, Ogino I, Nakamura E, Tada N, Kunichika M, Arai H. Leucine-rich a2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLOS ONE. 2013 Sep; 8(9): e74453.

    5. Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, Arai H: Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. Eur J Neurol. 20(2): 236-242,2013

    6. Watanabe M, Miyajima M, Ogino I, Nakajima M, Arai H: Cerebellar Purkinje Cells Exhibit Increased Expression of HMGB-1 and Apoptosis in Congenital Hydrocephalic H-Tx Rats. Neurosurgery. 72(3): 459-467, 2013

    7. Miyajima M, Nakajima M, Motoi Y, Moriya M, Sugano H, Ogino I, Nakamura E, Tada N, Kunichika M, Arai H : Leucine-rich α2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLoS One. 2013 Sep 18;8(9):e74453

    8. Hoshi K, Kariya Y, Nara K, Ito H, Matsumoto K, Nagae M, Yamaguchi Y, Nakajima M, Miyajima M, Arai H, Kuno A, Narimatsu H, Shirotani K, Hashimoto Y: Lectin-dependent inhibition of antigen-antibody reaction: application for measuring α2,6-sialylated glycoforms of transferrin. J Biochem. 2013 Sep;154(3):229-32.

    9. Tsutsumi S, Ogino I, Miyajima M, Ikeda T, Shindo N, Yasumoto Y, Ito M, Arai H. Genomic causes of multiple cerebral cavernous malformations in a Japanese population. J Clin Neurosci. 2013 May;20(5):667-9.

    10. Shimoji K, Kimura T, Kondo A, Tange Y, Miyajima M, Arai H: Genetic studies of myelomeningocele. Childs Nerv Syst. 2013 Sep;29(9):1417-25.

    11. Nakanishi A, Fukunaga I, Hori M, Masutani Y, Takaaki H, Miyajima M, Aoki S: Microstructural changes of the corticospinal tract in idiopathic normal pressure hydrocephalus: a comparison of diffusion tensor and diffusional kurtosis imaging. Neuroradiology. 2013 Aug;55(8):971-6.

    12. Shibata N, Nagata T, Shinagawa S, Ohnuma T, Shimazaki H, Komatsu M, Kuerban B Tomson K, Nakayama K, Yamada H, Arai H.Genetic association between APOA1 and APOD polymorphisms and Alzheimer’s disease in a Japanese population.J Neural Transm.2013:120(11):1599-1603.

    13. Nagata T, Shibata N, Shinagawa S, Nakayama R, Kuerban B, Ohnuma T, Arai H, Nakayama K, Yamada H. Genetic Association between Neurotrophin-3 Polymorphisms and Alzheimer’s Disease in Japanese Patients. Dement Geriatr Cogn Dis Extra.2013:3:272-280.

    14. Ohnuma T, Takebayashi Y, Higashiyama R, Shibata N, Arai H. Low-dose lamotrigine augmentation therapy improves residual symptoms in treatment-resistant schizophrenia: A report of five cases Asia-Pacific. Psychiatry.2013.5:336–343.

    15. Nobuto Shibata, Yumiko Motoi, Hiroyuki Tomiyama, Tohru Ohnuma, Bolati Kuerban, Katrin Tomson, Miwa Komatsu, Hiromi Shimazaki, Nobutaka Hattori, Heii Arai.Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer’s Disease and Parkinson’s Disease with Dementia.Dement Geriatr Cogn Dis Extra.2013:May 18;3(1):161-7.

    16. Nagata T, Shinagawa S, Kuerban B, Shibata N, Ohnuma T, Arai H, Nakayama K,YamadaH.Age-Related Association between Apolipoprotein E ε4 and Cognitive Function in Japanese Patients with Alzheimer’s Disease.　Dement Geriatr Cogn Dis Extra. 2013:Jan;3(1):66-73.

    17. Bian Z, Furuya N, Zheng D-M, Oliva Trejo JA, Tada N, Ezaki J, Ueno T. Ferulic acid induces mTor inactivation in cultured mammalian cells. Biol Pharm Bull. 2013; 36(1): 120-124.

    18. Kawano S, Lin Q, Amano H, Kaneko T, Nishikawa K, Tsurui H, Tada N, Nishimura H, Takai T, Shirai T, Takasaki Y, Hirose S. Phenotype conversion from rheumatoid arthritis to systemic lupus erythematosus by introduction of Yaa mutation into FcgRIIB-deficient C57BL/6 mice. Eur J Immunol. 2013 Mar; 43(3): 770-778.

    19. Koike M, Tanida I, Nanao T, Tada N, Iwata J-I, Ueno T, Kominami E and Uchiyama Y. Enrichment of GABARAP relative to LC3 in the axonal initial segments of neurons. PLOS ONE. 2013 May; 8(5): e63568.

    20. Miyajima M, Nakajima M, Motoi Y, Moriya M, Sugano H, Ogino I, Nakamura E, Tada N, Kunichika M, Arai H. Leucine-rich a2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLOS ONE. 2013 Sep; 8(9): e74453.

    21．Hirose S, Watanabe T, Wada H, Imai Y, Machida T, Shirouzu I, Miyashita Y, Konishi S. Functional relevance of micromodules in the human association cortex delineated with high-resolution fMRI. Cerebral Cortex, 23, 2863-2871, 2013

    22. Hirose S, Kimura H. M, Jimura K, Kunimatsu A, Abe O, Ohtomo K, Miyashita Y, Konishi S. Dissociable temporo-parietal memory networks revealed by functional connectivity during episodic retrieval. PLoS ONE, 8, e71210, 2013

    23．Watanabe T, Hirose S, Wada H, Imai Y, Machida T, Shirouzu I, Konishi S, Miyashita Y, Masuda N. A pairwise maximum entropy model accurately describes resting-state human brain networks. Nature Communications, 4, 1370, 2013

    24．Uchimura M, Kitazawa S. Cancelling prism adaptation by a shift of background: a novel utility of allocentric coordinates for extracting motor errors. J Neurosci. 33: 7595-7602, 2013.

    25． Mitani A, Sasaki R, Oizumi M, Uka T. A leaky-integrator model as a control mechanism underlying flexible decision making during task switching. PLoS ONE. 8: e59670, 2013.

    26. Ando K ,Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, Takahashi K.Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating CancerCachexia. Journal of Clinical Oncology. 2013; 31(6): 69-72.

    27. Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, Doi T, Iwakami S, Takahashi K, Seyama K, Mikami M.The efficacy and safety of low-dose sirolimus in lymphangioleiomyomatosis. Respiratory Investigation. 2013; 51(3): 175-83.

    28. Ando K, Motojima S, Doi T, Nagaoka T, Kaneko N, Aoshima M, Takahashi K. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respiratory Investigation. 2013; 51(2): 69-75.

    29. Ando K, Sekiya M, Tobino K, Takahashi K.Relationship Between Quantitative CT Metrics and Pulmonary Function in Combined Pulmonary Function in Combined Pulmonary Fibrosis and Emphysema.Lung.2013; 19(6): 585-91.

    30. Babaei Jandaghi A, Daliri S, Kikkawa M, Khaledi M, Soleimanifar N, Alizadeh A, Habibzadeh M, Haghi-Ashtiani MT, Seyama K, Rezaei N.The discovery of a Persian family with a form of Birt-Hogg-Dubé syndrome lacking the typical cutaneous stigmata of the syndrome. Clin Imaging. 2013; 37: 111-115.

    31. Harada M, Akimoto K, Otaka M, Sato K, Oda H, Otsuki M, Takahashi K, Kishiro M, Shimizu T. Thrombolytic therapy in Kawasaki disease: a report of four cases. Pediatr Int. 2013 Oct; 55(5): e111-5.

    32. Hoshika Y, Hamamoto T, Sato K, Eto H, Kuriyama S, Yoshimi K, Iwakami S, Takahashi K, Seyama K. Prevalence and clinical features of lymphedema in patients with lymphangioleiomyomatosis. Respir Med. 2013; 107(8): 1253-1259.

    33. Imai H, Shukuya T, Yoshino R, Muraki K, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Tomizawa Y, Takahashi T, Takahashi K, Saito R, Yamamoto N.Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.Chemotherapy. 2013; 59(4): 307-13.

    34. Iwakami S, Fujii M, Ishiwata T, Iwakami N, Hara M, Ihara H, Wada R, Tsutsumi T, Seyama K, Takahashi K.Small-cell Lung Cancer Exhibiting Spontaneous Regression.Reprinted from Internal Medicine. 2013 Oct; 52(19): 2249-2252.

    35. Ishiwata T, Seyama K, Hirao T, Shimada K, Morio Y, Miura K, Kume A, Takagi H, Takahashi K. Improvement in skin color achieved by smoking cessation. Int J Cosmet Sci. 2013; 35(2): 191-5.

    36. Kato M, Tobino K, Fujimoto Y, Kobayashi I, Sugano K, Tokuda H, Ienaga H, Takahashi K. Pneumocystis pneumonia induced by treatment with low-dose tacrolimus and methylprednisolone in a patient with rheumatoid arthritis: a case report. BMC Res Notes. 2013; 6(1): 498.

    37. Mochizuki H, Nanjo Y, Takahashi H.Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly COPD patients. Geriat Geront Int. 2013; 398-404.

    38. Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J Thorac Dis. 2013; 5(2): 145-148.

    39. Nagahama KY, Togo S, Holz O, Magnussen H, Liu X, Seyama K, Takahashi K, Rennard SI. Oncostatin M modulates fibroblast function via signal ttransducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol. 2013; 49(4): 582-591.

    40. Nagashima O, Matsuno K, Tominaga S, Takahashi K.Esophageal diverticulum with idiopathic pulmonary upper lobe fibrosis. Intern Med. 2013; 52(1): 159..

    41. Nagashima O, Ohashi R, Yoshioka Y, Inagaki A, Tajima M, Koinuma Y, Iwakami S, Iwase A, Sasaki S, Tominaga S, Takahashi K.High prevalence of gene abnormalities in young patients with lung cancer. J Thorac Dis. 2013; 5(1): 27-30.

    42. Nanjo Y, Ishii Y, Kimura S, Fukami T, Mizoguchi M, Suzuki T, Tomono K, Akasaka Y, Ishii T, Takahashi K, Tateda K, Yamaguchi K.Effects of slow-releasing colistin microspheres on emdotoxin-induced sepsis. J Infect Chemother. 2013; 19(4): 683-90.

    43. Sasaki M,Mochizuki H,Takahashi H.Bronchoesoph ageal fistula developing shortly after initiation of antituberculous chemotherapy.Internal Medicine. 2013; 52: 376-380.

    44. Sekiya M, Yoshimi K, Muraki K, Suzuki K, Dambara T, Toshimasa U, Takahashi K. Solitary Fibrous Tumor of the Pleura: Ultrasonographic Imaging Findings of Three Cases. Respiratory Investigation. 2013; 51(3): 200-204.

    45. Shiota S, Takekawa H, Matsumoto S,Takeda K, Nurwidya F, Yoshioka Y, Takahashi F, Hattori N, Tabira T, Mochizuki H, Takahashi K.Chronic Intermittent Hypoxia/Reoxygenation Facilitate Amyloid-β Generation in Mice.Journal of Alzheimer’s Disease 2013; 37: 325-333.

    46. Shukuya T, Takahashi T, Harada H, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N. Chemoradiotherapy for limited-desease small-cell lung cancer in elderly patients aged 75 years or older. Jpn J Clin Oncol. 2013; 43(2): 176-183.

    47. Suzuki K, Seyama K, Hayashi T, Yamashiro Y, Shiraishi A, Kuwatsuru R.Reversed halo sign in tuberous sclerosis complex.Case Rep Radiol. 2013; 428501.

    48. Togo S, Polanska U, Horimoto Y, Orimo A.Cancer-associated fibroblasts are promising thrapeutic target.　Cancers Jun. 2013; 5: 149-169.

    49. Douet V, Arikawa-Hirasawa E, Mercier F Fractone-heparan sulfates mediate FGF-2 stimulation of cell proliferation in the adult subventricular zone. Cell Prolif. 46:137-45. 2013 IF:3.116

    50. Nakazawa N, Miyahara K, Okawada M, Yamataka A, Suzuki R, Akazawa C, Tomikawa-Ichikawa N, Arikawa-Hirasawa E. Laminin-1 promotes enteric nervous system development in mouse embryo. Pediatr Surg Int. 29:1205-8. 2013 IF:0.995

    51. Nishizaki Y, Yamagami S, Myojin M, Sesoko M, Yamashita H, Suzuki R, Daida H. A murmur-free giant myxoma discovered incidentally on abdominal ultrasonography. Intern Med. 2013;52(22):2529-31.

    52. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan–2012 version. J Atheroscler Thromb. 2013;20(12):835-49.

    53. Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Sugioka T, Kawai S; all ACCEPT study investigators in Japan. Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. Circ J. 2013 Dec 25;78(1):194-205.

    54. Nishizaki Y, Daimon M, Miyazaki S, Suzuki H, Kawata T, Miyauchi K, Chiang SJ, Makinae H, Shinozaki T, Daida H. Clinical factors associated with classical symptoms of aortic valve stenosis. J Heart Valve Dis. 2013 May;22(3):287-94.

    55. Yang B, Daimon M, Ishii K, Kawata T, Miyazaki S, Hirose K, Ichikawa R, Chiang SJ, Suzuki H, Miyauchi K, Daida H. Prediction of coronary artery stenosis at rest in patients with normal left ventricular wall motion. Segmental analyses using strain imaging diastolic index. Int Heart J. 2013;54(5):266-72.

    56. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan–2012 version. J Atheroscler Thromb. 2013;20(12):850-60.

    57. Kawata T, Daimon M, Hasegawa R, Toyoda T, Sekine T, Himi T, Uchida D, Miyazaki S, Hirose K, Ichikawa R, Maruyama M, Suzuki H, Daida H. Prognostic value of coronary flow reserve assessed by transthoracic Doppler echocardiography on long-term outcome in asymptomatic patients with type 2 diabetes without overt coronary artery disease. Cardiovasc Diabetol. 2013 Aug 27;12:121.

    58. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Other high-risk conditions. J Atheroscler Thromb. 2013 Nov 25;20(11):785-9.

    59. Ohno I, Hayashi H, Aonuma K, Horio M, Kashihara N, Okada H, Komatsu Y, Tamura S, Awai K, Yamashita Y, Kuwatsuru R, Hirayama A, Saito Y, Murohara T, Tamaki N, Sato A, Takayama T, Imai E, Yasuda Y, Koya D, Tsubakihara Y, Horie S, Korogi Y, Narumi Y, Hayakawa K, Daida H, Node K, Kubota I; Japanese Society of Nephrology, Japan Radiological Society, and Japanese Circulation Society Science Advisory and Coordinating Committee. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group. Clin Exp Nephrol. 2013 Aug;17(4):441-79.

    60. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Absolute risk of cardiovascular disease and lipid management targets. J Atheroscler Thromb. 2013;20(9):689-97.

    61. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan – 2012 version. J Atheroscler Thromb. 2013;20(10):733-42.

    62. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Diagnostic criteria for dyslipidemia. J Atheroscler Thromb. 2013 Aug 26;20(8):655-60.

    63. Ohno I, Hayashi H, Aonuma K, Horio M, Kashihara N, Okada H, Komatsu Y, Tamura S, Awai K, Yamashita Y, Kuwatsuru R, Hirayama A, Saito Y, Murohara T, Tamaki N, Sato A, Takayama T, Imai E, Yasuda Y, Koya D, Tsubakihara Y, Horie S, Korogi Y, Narumi Y, Hayakawa K, Daida H, Node K, Kubota I; Japanese Society of Nephrology; Japan Radiological Society; Japanese Circulation Society. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group. Jpn J Radiol. 2013 Aug;31(8):546-84.

    64. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society (JAS). Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan — 2012. J Atheroscler Thromb. 2013 Jul 30;20(7):603-15.

    65. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, I ida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb. 2013;20(6):517-23.

    66. Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Tsukahara K, Origasa H, Morino Y, Tsutsui H, Kobayashi M, Isshiki T; PACIFIC investigators. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J. 2013;77(4):934-43.

    67. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M; Justification For Atherosclerosis Regression Treatment (JART) Investigators. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness–Justification for Atherosclerosis Regression Treatment (JART) extension study. Circ J. 2013;77(6):1526-33.

    68. Nishizaki Y, Yamagami S, Joki Y, Takahashi S, Sesoko M, Yamashita H, Yokoyama T, Uehara Y, Daida H. Japanese features of native valve endocarditis caused by coagulase-negative staphylococci: case reports and a literature review. Intern Med. 2013;52(5):567-72.

    69. Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, Chiang SJ, Suzuki H, Ito C, Sato F, Watada H, Daida H. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013 Feb 27;12:38.

    70. Daida H, Iwase T, Yagi S, Ando H, Nakajima H. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Circ J. 2013;77(6):1518-25.

    71. Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yokoi H, Yoshida M; Justification for Atherosclerosis Regression Treatment (JART) Investigators. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. Int Heart J. 2013;54(1):33-9.

    72. Kawashiri MA, Yamagishi M, Sakamoto T, Takayama T, Hiro T, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Ther. 2013 Dec;31(6):335-43.

    73. Miura Y, Fukumoto Y, Miura T, Shimada K, Asakura M, Kadokami T, Ando S, Miyata S, Sakata Y, Daida H. Matsuzaki M, Yasuda S, Kitakaze M, Shimokawa H. Impact of Physical Activity on Cardiovascular Events in Patients with Chronic Heart Failure -A Multi-center Prospective Cohort Study-. Circ J. 77: 2963-2972;2013.

    74. Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Kurano M, Kishimoto T, Yanagisawa N, Ogita M, Miyazaki T, Nishino A, Yaginuma K, Tamura H, Kojima T, Yokoyama K, Kurata T, Shimada K, Daida H, Yatomi Y. Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. Atherosclerosis. 229:192-7;2013.

    75. Sai E, Shimada K, Yokoyama T, Sato S, Miyazaki T, Hiki M, Tamura Y, Aoki S, Watada H, Kawamori R, Daida H. Association between Myocardial Triglyceride Content and Cardiac Function in Healthy Subjects and Endurance Athletes. PLOS ONE. 8:e61604;2013.

    76. Nishitani M, Shimada K, Sunayama S, Masaki Y, Kume A, Fukao K, Sai E, Yamashita H, Ohmura H, Onishi T, Shioya M, Sato H, Shimada A, Yamamoto T, Amano A, Daida H. Effect of cardiac rehabilitation on muscle mass, muscle strength, and exercise tolerance in diabetic patients after coronary artery bypass grafting. J Cardiol. 61:216-221;2013.

    77. Matsumori R, Miyazaki T, Shimada K, Kume A, Kitamura Y, Oshida K, Yanagisawa N, Kiyanagi T, Hiki M, Fukao K, Hirose K, Ohsaka H, Mokuno H, Daida H. High levels of very long-chain saturated fatty acid in erythrocytes correlates with atherogenic lipoprotein profiles in subjects with metabolic syndrome. Diabetes Res Clin Pract. 99:12-18;2013.

    78. Ogita M, Miyauchi K, Dohi T, Tsuboi S, Miyazaki T, Yokoyama T, Yokoyama K, Shimada K, Kurata T, Jiang M, Bujo H, Daida H. Increased circulating soluble LR11 in patients with acute coronary syndrome. Clin Chim Acta. 415:191-194;2013.

    79. Sumi S, Origasa H, Houkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Miyamoto S, Minematsu K, Matsumoto M, Okada Y, Sato M, Suzuki N. A modified Essen stroke risk score for predicting recurrent cardiovascular events: development and validation. Int J Stroke. 2013 in press

    80. Sugihara M, Odagiri F, Suzuki T, Murayama T, Nakazato Y, Unuma K, Yoshida K, Daida H, Sakurai T, Morimoto S, Kurebayashi N. Usefulness of running wheel for detection of congestive heart failure in dilated cardiomyopathy mouse model. PLoS One. 8:e55514;2013.

    81. Kawata T, Konishi H, Amano A, Daida H. Wavering calcified amorphous tumour of the heart in a haemodialysis patient. Interact Cardiovasc Thorac Surg. 16:219-20;2013.

    82. Tsuboi S, Miyauchi K, Kasai T, Ogita M, Dohi T, Miyazaki T, Yokoyama T, Kojima T, Yokoyama K, Kurata T, Daida H. Impact of red blood cell distribution width on long-term mortality in diabetic patients after percutaneous coronary intervention. Circ J. 77:456-61;2013.

    83. Kasai T, Miyauchi K, Yanagisawa N, Kajimoto K, Kubota N, Ogita M, Tsuboi S, Amano A, Daida H. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart. 99:22-9;2013.

    84. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M; JAPAN-ACS Investigators. Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study. Cardiovasc Diabetol. 12:5;2013.

    85. Ogita M, Miyauchi K, Morimoto T, Daida H, Kimura T, Hiro T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M. Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome–subanalysis of the JAPAN-ACS study. Atherosclerosis. 226:275-80;2013.

    86. Nonomura K, Yamaguchi Y, Hamachi M, Koike M, Uchiyama Y, Nakazato K, Mochizuki A, Sakaue-Sawano A, Miyawaki A, Yoshida H, Kuida K, Miura M (2013) Local apoptosis modulates early mammalian brain development through the elimination of morphogen-producing cells. Dev Cell 27: 621-634

    87. Abe H, Uchida T, Hara A, Mizukami H, Komiya K, Koike M, Shigihara N, Toyofuku Y, Ogihara T, Uchiyama Y, Yagihashi S, Fujitani Y, Watada H. (2013) Exendin-4 improves beta cell function in autophagy-deficient beta cells. Endicrinology 154: 4512-4524

    88. Sakata K, Ohmuraya M, Araki K, Suzuki C, Ida S, Hashimoto D, Wang J, Uchiyama Y, Baba H, Yamamura K (2013) Generation and analysis of serine protease inhibitor Kazal type 3-Cre driver mice. Exp Animals.

    89. Okura H, Kobayashi T, Koike M, Ohsawa M, Zhang D, Arai H, Uchiyama Y, Hino O (2013) Tuberin activates and controls the distribution of Rac1 via association with p62 and ubiquitin through the mTORC1 signaling pathway. Int J Oncol 43: 447-456

    90. Adachi T, Takahara K, Taneo J, Uchiyama Y, Inaba K (2013) Particle size of latex beads dictates IL-1b production mechanism. PLos One 8(7):e68499

    91. Koike M, Tanida I, Nanao N, Tada N, Iwata J, Ueno T, Kominami E, Uchiyama Y (2013) Enrichment of GABARAP relative to LC3 in the axonal initial segments of neurons. PLos One 8:e63568 (*equally contributed)

    92. *Matsui, H., *Sato, F., Sato, S., Koike, M., Taruno, Y., Saiki, S., Funayama, M., Ito, H., Taniguchi, Y., Uemura, N., Toyoda, A., Sakaki, Y., Takeda, S., Uchiyama, Y., Hattori, N., Takahashi, R. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS letters 587(9):1316-25, 2013. (*These authors contributed equally to this work)

    93. Ohkouchi S, Shibata M, Sasaki M, Koike M, Safig P, Peters C, Nagata S, Uchiyama Y (2013) Biogenesis and proteolytic processing of lysosomal DNase II. PLos One, 8:e59148

    94. Furuta A, Wakabayashi K, Haratake J, Kikuchi H, Kabuta T, Mori F, Tokonami F, Katsumi Y, Tanioka F, Uchiyama Y, Nishino I, Wada K (2013) Lysosomal storage and advanced senescence in the brain of LAMP-2-deficient Danon disease. Acta Neuropathol, 125:459-461

    95. Koike M, Shibata M, Ezaki J, Peters C, Saftig P, Kominami E, Uchiyama Y (2013) Differences in expression patterns of cathepsin C/dipeptidyl peptidase I in normal, pathological and aged mouse central nervous systems. Eur J Neurosci, 37:816-830